多西他赛联合希罗达治疗复发转移性乳腺癌的临床观察

The Clinical Study of Docetaxel-Xeloda Combination in Treatment of in the Treatment of Metastatic Breast Cancer

目的:对于复发转移性乳腺癌,多西他赛和希罗达药物均有确切肯定的疗效,由于多西他赛能增强肿瘤组织的胸苷磷酸化酶(TP)活性,因而与希罗达有协同作用。本研究观察及评价多西他赛联合希罗达治疗复发转移性乳腺癌的疗效和不良反应。方法:32例复发转移性乳腺癌患者均给予多西他赛75mg/m2,第1天;希罗达口服2次/d,餐后服用,每次1250mg/m2,连续服用14d,治疗周期为21d,至少治疗2个周期。结果:本组完全缓解(CR)2例,部分缓解(PR)15例,稳定(SD)4例,疾病进展(PD)10例,总有效率53.1%,中位疾病进展时间(TTP)10个月。不同转移部位或器官的有效率分别为:软组织62.7%(10/16);肺脏50%(9/18);骨骼54.5%(6/11);肝脏30.0%(7/13)。常见不良反应为手足综合征、皮肤色素沉着、恶心、呕吐、厌食、疲劳,少数患者出现口炎、头晕、腹泻和胸闷。90.6%的患者有白细胞下降,2例Ⅳ度骨髓抑制。结论:多西他赛联合希罗达治疗晚期乳腺癌疗效肯定,患者耐受性良好。

Objective It is confirmed that Docetaxel and Xeleda have effect on the metastatic breast cancer respectively. The Docetaxel can increase the active of hymidine phosphorylase in the tumour, so it will help the Xeloda to kill tumour cells. Our study is to evaluate the efficacy and toxicity of Docetaxel-Xeloda combination chemotherapy onmetastatic breast cancer. Methods 32 patients with metastatic breast cancer were treated with Docetaxel and Xeloda combination regimen. Dcetaxel 75 mg/m^2 ivgtt, d1 ; Xeleda was given at a dose of or 1 250 mg/m^2/d,bid,A. C. ,for twoweeks followed by one week rest as one cycle, at least for two cycle in each patient. Efficiency and toxicity were observed in everycycle. Results Among these 32 patients, there was 3 complete response. Rates of partial response 15, stable disease 4, progressive disease 10, and clinical benefit response （ CR ＋ PR） 56.1%. The meso progression of disease time（TIP） is 10 months. The effective power of diffrent metastatic organs are respectively：soft tissue 62.7% （10/16）, lung 50% （9/18） ,ossature 54.5% （6/11） ,liver 30.0% （7/13）. The common adverse reactions were hand-foot syndrome, skin pigmentation, nausea, vomiting, diarrhoea. Leukopenia were observed in 90.6 % of patients. Tow patients developed degree Ⅳ myelosuppression. Conclusion The combination of Docetaxel and Xelodais an effective regimen for patients with metastatic breast cancer. The toxicities are tolerable to the majority of patients.